Frazier Life Sciences Management L.P. Trims Stock Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Frazier Life Sciences Management L.P. trimmed its holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 23.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 955,515 shares of the company's stock after selling 295,271 shares during the quarter. Frazier Life Sciences Management L.P. owned approximately 2.89% of Lexeo Therapeutics worth $6,287,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of LXEO. Janus Henderson Group PLC increased its stake in Lexeo Therapeutics by 15.3% in the fourth quarter. Janus Henderson Group PLC now owns 4,339,254 shares of the company's stock valued at $28,508,000 after purchasing an additional 576,059 shares during the period. Altium Capital Management LLC purchased a new position in shares of Lexeo Therapeutics during the fourth quarter worth about $2,665,000. Point72 Asset Management L.P. increased its position in Lexeo Therapeutics by 102.5% in the 4th quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company's stock valued at $4,937,000 after acquiring an additional 379,828 shares during the period. Vestal Point Capital LP raised its stake in Lexeo Therapeutics by 41.2% during the 4th quarter. Vestal Point Capital LP now owns 1,200,000 shares of the company's stock valued at $7,896,000 after acquiring an additional 350,000 shares during the last quarter. Finally, DAFNA Capital Management LLC lifted its position in Lexeo Therapeutics by 56.9% during the 4th quarter. DAFNA Capital Management LLC now owns 393,083 shares of the company's stock worth $2,586,000 after acquiring an additional 142,500 shares during the period. Hedge funds and other institutional investors own 60.67% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on LXEO. HC Wainwright dropped their price objective on shares of Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Leerink Partners dropped their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research note on Monday, March 24th. Royal Bank of Canada reduced their price objective on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research report on Tuesday, March 25th. Finally, Chardan Capital dropped their target price on Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $20.20.

Lexeo Therapeutics Price Performance

LXEO stock traded down $0.26 during trading on Monday, reaching $2.82. 480,722 shares of the company were exchanged, compared to its average volume of 490,973. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. The stock's 50 day moving average price is $3.09 and its 200 day moving average price is $4.75. Lexeo Therapeutics, Inc. has a 52-week low of $1.45 and a 52-week high of $19.50. The company has a market cap of $93.62 million, a P/E ratio of -0.89 and a beta of 1.27.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.19). As a group, analysts predict that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current fiscal year.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.